Galapagos Reports First Patients Dosing with GLPG3970 (Toledo Compound) for Psoriasis

 Galapagos Reports First Patients Dosing with GLPG3970 (Toledo Compound) for Psoriasis

Galapagos Reports First Patients Dosing with GLPG3970 (Toledo Compound) for Psoriasis

Shots:  

  • The company has reported the first patient dosing in the P-I CALOSOMA study assessing the safety, tolerability, PK/PD of GLPG3970 single & multiple ascending doses in up to 52 adult healthy male subjects. The therapy will now be evaluated in 25 patients with moderate to severe psoriasis for 6wks.
  • Galapagos is also evaluating the potential of GLPG3970 in the P-II SEA TURTLE study for patients with mod. to sev. active UC and in P-II LADYBUG study for patients with severely active RA who had an inadequate response to MTX
  • Galapagos plans to unveil the novel Toledo target class and will share GLPG3970 P-I data at its inaugural Toledo Roundtable to be held virtually on Oct 27, 2020

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: European Technology

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post